Document is current
Any future updates will be listed below
-
Authors
Cheslow, Lara http://orcid.org/0000-0003-0880-5957
Byrne, Matthew
Kopenhaver, Jessica S.
Iacovitti, Lorraine
Smeyne, Richard J. http://orcid.org/0000-0002-8459-5472
Snook, Adam E. http://orcid.org/0000-0001-9216-4560
Waldman, Scott A. http://orcid.org/0000-0001-6619-175X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (1R01 CA206026, 1R21 1NS130388, 1R21 CA267087-01)
U.S. Department of Health & Human Services | National Institutes of Health
United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (W81XWH-17-PRCRP-TTSA, W81XWH-19-1-0263)
American Parkinson Disease Association (PF-IMP-1045175)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (F30NS125921)
Pharmaceutical Research and Manufacturers of America Foundation (2021 PDDS 725469)
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 6 October 2023
Accepted: 26 March 2024
First Online: 13 April 2024
Competing interests
: S.A.W. is a member of the Board of Directors and A.E.S. is a consultant for, Targeted Diagnostics & Therapeutics, Inc., which provided research funding that, in part, supported this work and has a license to commercialize inventions related to this work. R.J.S. is Associate Editor of npj Parkinson’s Disease. R.J.S. was not involved in the journal’s review of, or decisions related to, this manuscript. The remaining authors declare no competing interests.
